keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic Weight Gain

keyword
https://www.readbyqxmd.com/read/28540050/effect-of-atypical-antipsychotics-on-body-weight-in-geriatric-psychiatric-inpatients
#1
Eugene Yh Yeung, Soojin Chun, Alan Douglass, Timothy E Lau
BACKGROUND: Studies suggest that antipsychotic-induced weight gain is not a great concern in the elderly population. This study investigated the weight change in elderly patients with various treatment duration and antipsychotics. Part 1 of the study was to determine whether atypical antipsychotics induced weight change in elderly patients. Part 2 was to determine whether certain atypical antipsychotics induced more weight change in elderly patients. METHODS: In Part 1, a retrospective chart review was done on 115 geriatric inpatients...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28531893/association-study-of-serotonin-3-receptor-subunit-gene-variants-in-antipsychotic-induced-weight-gain
#2
Clement C Zai, Arun K Tiwari, Nabilah I Chowdhury, Eva J Brandl, Sajid A Shaikh, Natalie Freeman, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Daniel J Müller
BACKGROUND: Schizophrenia (SCZ) is a chronic severe neuropsychiatric disorder, where pharmacological treatment has been hindered by adverse effects, including antipsychotic-induced weight gain (AIWG) and related complications. Genetic studies have been exploring the appetite regulation and energy homeostasis pathways in AIWG with some promising leads. The serotonin system has been shown to participate in these pathways. METHODS: In the current study, we examined single nucleotide polymorphisms across the serotonin receptor genes HTR3A and HTR3B...
May 23, 2017: Neuropsychobiology
https://www.readbyqxmd.com/read/28507773/rapid-onset-clozapine-induced-loss-of-glycaemic-control-case-report
#3
Alejandro Porras-Segovia, Amir Krivoy, Mark Horowitz, George Thomas, Mark Bolstridge, Dragos Ion, Sukhwinder S Shergill
Clozapine has proved to be an effective antipsychotic for the treatment of refractory schizophrenia - characterised by the persistence of symptoms despite optimal treatment trials with at least two different antipsychotics at adequate dose and duration - but its use is hampered by adverse effects. The development of clozapine-induced diabetes is commonly considered to arise as part of a metabolic syndrome, associated with weight gain, and thus evolves slowly. We present the case of an individual with refractory schizophrenia and metformin-controlled diabetes who developed rapid-onset insulin-dependent hyperglycaemia immediately after starting clozapine...
May 2017: BJPsych Open
https://www.readbyqxmd.com/read/28498089/changes-in-bmi-in-hospitalized-patients-during-treatment-with-antipsychotics-depending-on-gender-and-other-factors
#4
Lenka Sušilová, Eva Češková, David Hampel, Aleš Sušil, Jan Šimůnek
OBJECTIVE: To investigate the differences in body mass index (BMI) changes between men and women during hospitalization. METHODS: The retrospective study monitored demographic and clinical data of 462 schizophrenic patients hospitalized 737 times between 2006 and 2011. BMI analysis was performed on patients on antipsychotic medication hospitalized longer than four days. RESULTS: Patients with an initial BMI < 25 gained more weight than patients with a BMI > 25 (3...
February 24, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28478771/evaluation-of-the-long-term-safety-and-tolerability-of-cariprazine-in-patients-with-schizophrenia-results-from-a-1-year-open-label-study
#5
Andrew J Cutler, Suresh Durgam, Yao Wang, Raffaele Migliore, Kaifeng Lu, István Laszlovszky, György Németh
OBJECTIVE: Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. The efficacy and safety of cariprazine was established in three randomized, double-blind, placebo-controlled, 6-week trials in patients with acute exacerbation of schizophrenia. This 53-week study evaluated the long-term safety and tolerability of cariprazine in patients with schizophrenia...
May 8, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28469583/commentary-a-randomized-double-blind-placebo-controlled-trial-of-metformin-treatment-of-weight-gain-associated-with-initiation-of-atypical-antipsychotic-therapy-in-children-and-adolescents
#6
COMMENT
https://www.readbyqxmd.com/read/28463344/minimizing-weight-gain-for-patients-taking-antipsychotic-medications-the-potential-role-for-early-use-of-metformin
#7
Victoria Hendrick, Robert Dasher, Michael Gitlin, Mehrban Parsi
BACKGROUND: Patients taking antipsychotic medications are at high risk for weight gain, which in turn leads to poor health outcomes, nonadherence with treatment, and low self-esteem. METHODS: We reviewed published studies of pharmacologic interventions aimed at minimizing antipsychotic-induced weight gain. Treatments initiated prior to onset of weight gain were compared with those that started once weight gain already had occurred. RESULTS: Although data are limited, adjunctive medications for weight management appear to be more effective when initiated at or near the time when patients are first exposed to antipsychotic medications...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28455891/paliperidone-palmitate-effectiveness-safety-and-the-use-for-treatment-of-schizophrenia
#8
REVIEW
Marek Jarema, Przemysław Bieńkowski, Janusz Heitzman, Tadeusz Parnowski, Janusz Rybakowski
The aim of the study was to summarize the efficacy and tolerability of paliperidone palmitate, an atypical long-acting antipsychotic drug. Paliperidone is a 9-hydroxy metabolite of risperidone with a slightly different receptor profile and significantly different pharmacokinetic profile. After the short review of its pharmacological properties, the efficacy of the drug in comparison to placebo or to an active comparator was described. The studies revealed the effectiveness of paliperidone palmitate in the treatment of psychotic symptoms, mainly schizophrenia...
February 26, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/28453334/different-immune-signature-in-youths-experiencing-antipsychotic-induced-weight-gain-compared-to-untreated-obese-patients
#9
Simone Pisano, Gennaro Catone, Giangennaro Coppola, Marco Carotenuto, Raffaella Iuliano, Claudia Tiano, Anna Rita Montesanto, Vittoria D'Esposito, Emanuele Del Giudice Miraglia, Pietro Formisano, Carmela Bravaccio
OBJECTIVES: To assess cytokine and chemokine levels in youth experiencing antipsychotic-induced weight gain (AIWG) compared to obese patients, hypothesizing a different "immune signature" between the two kinds of obesity. METHODS: We compared a group of youth experiencing AIWG (N 19, mean age 159 months, mean body mass index [BMI] z-score 1.81) and an age-, gender-, and BMI-matched group of untreated obese patients (N 19, mean age 147 months, mean BMI z-score 2) for a wide range of cytokines and chemokines by using a multiplex ELISA test...
April 28, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28449560/assessment-of-the-latent-adverse-events-of-antipsychotic-treatment-using-a-subjective-questionnaire-in-japanese-patients-with-schizophrenia
#10
Masakazu Hatano, Hiroyuki Kamei, Azusa Kato, Ippei Takeuchi, Manako Hanya, Junji Uno, Shigeki Yamada, Kiyoshi Fujita, Nakao Iwata
Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we. investigated the adverse events of antipsychotics that are less likely to be reported by patients and the reasons why such symptoms remain latent. Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated. Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28447303/brief-report-metformin-for-antipsychotic-induced-weight-gain-in-youth-with-autism-spectrum-disorder
#11
Logan K Wink, Ryan Adams, Ernest V Pedapati, Kelli C Dominick, Emma Fox, Catherine Buck, Craig A Erickson
Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD...
April 26, 2017: Journal of Autism and Developmental Disorders
https://www.readbyqxmd.com/read/28443526/transformation-of-excess-mortality-in-people-with-schizophrenia-and-bipolar-disorder-in-taiwan
#12
Y-J Pan, L-L Yeh, H-Y Chan, C-K Chang
BACKGROUND: Given the concerns regarding the adverse health outcomes associated with weight gain and metabolic syndrome in relation to use of second-generation antipsychotics (SGAs), we aimed in this study to explore whether the increase in the use of SGAs would have any impacts on the trend of excess mortality in people with schizophrenia and bipolar disorder (BPD). METHOD: Two nationwide samples of individuals with schizophrenia and BPD were identified in Taiwan's National Health Insurance Research Database in 2003 and in 2008, respectively...
April 26, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28437058/psychotic-and-bipolar-disorders-antipsychotic-drugs
#13
Sarah D Holder, Alaina L Edmunds, Sherri Morgan
Antipsychotic drugs block dopamine receptors and are used to manage psychosis as well as other mental illnesses that may or may not have psychotic features, such as bipolar disorders and major depressive disorder. First-generation antipsychotic drugs are more likely to cause adverse effects such as extrapyramidal symptoms and tardive dyskinesia. Adverse effects of second-generation antipsychotic drugs typically are related to metabolic abnormalities such as weight gain, abnormal blood glucose levels, and elevated lipid levels...
April 2017: FP Essentials
https://www.readbyqxmd.com/read/28408348/design-and-in-vivo-evaluation-of-solid-lipid-nanoparticulate-systems-of-olanzapine-for-acute-phase-schizophrenia-treatment-investigations-on-antipsychotic-potential-and-adverse-effects
#14
Emil Joseph, Satish Reddi, Vibhu Rinwa, Garima Balwani, Ranendra Saha
The present paper discusses the design, characterization and in vivo evaluation of glyceryl monostearate nanoparticles of Olanzapine, an atypical antipsychotic drug for acute schizophrenia treatment, during which hospitalization is mandatory and adverse effects are at its peak. The solid lipid nanoparticulate system was obtained by emulsification-ultra sonication technique wherein three factors such as solid lipid content, concentration of surfactant and drug: solid lipid ratio were selected at three different levels in order to study their influence on significant characteristic responses such as particle size, encapsulation efficiency and drug content...
April 11, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28407229/weight-gain-with-add-on-second-generation-antipsychotics-in-bipolar-disorder-a-naturalistic-study
#15
H Najar, E Joas, M Kardell, E Pålsson, M Landén
OBJECTIVE: Our aim was to investigate the prevalence and magnitude of weight gain in-patients with bipolar disorder when treated with a second-generation antipsychotic as an add-on treatment to a mood stabilizer in routine clinical practice. METHODS: Data were derived from the quality register for bipolar disorder in Sweden (BipoläR). Patients with bipolar disorder who started add-on treatment with a SGA (n = 575) were compared at next yearly follow-up with age and sex matched patients who were only treated with a mood stabilizer (n = 566)...
June 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28400260/prevention-of-the-adverse-effects-of-olanzapine-on-lipid-metabolism-with-the-antiepileptic-zonisamide
#16
Aneta Stefanidis, Matthew J Watt, Michael A Cowley, Brian J Oldfield
BACKGROUND: Atypical antipsychotic drugs, particularly olanzapine, represent a mainstay in the treatment of psychoses; however, their use is commonly associated with weight gain and diabetes. The aim of this study was to determine whether combined administration of olanzapine and zonisamide can be used to prevent olanzapine-induced metabolic disturbances. METHODS AND RESULTS: These experiments involved female Sprague Dawley rats (n = 6-8/group) that were administered olanzapine, either acutely (6 mg/kg, s...
April 8, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28383359/amantadine-for-antipsychotic-related-weight-gain-meta-analysis-of-randomized-placebo-controlled-trials
#17
Wei Zheng, Shibin Wang, Gabor S Ungvari, Chee H Ng, Xin-Hu Yang, Yu-Hong Gu, Ming Li, Ying-Qiang Xiang, Yu-Tao Xiang
PURPOSE: Weight gain associated with antipsychotics in schizophrenia has been an ongoing concern. This meta-analysis examined the efficacy and safety of amantadine as an adjunctive treatment of weight gain in schizophrenia by systematically searching and analyzing randomized controlled trials (RCTs). RCTs comparing adjunctive amantadine with placebo in adult patients with schizophrenia were included in the meta-analysis. METHODS: Two independent investigators searched the literature and extracted data...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28377074/metabolic-side-effects-induced-by-olanzapine-treatment-are-neutralized-by-cb1-receptor-antagonist-compounds-co-administration-in-female-rats
#18
P Lazzari, V Serra, S Marcello, M Pira, A Mastinu
Weight gain is an important side effect of most atypical antipsychotic drugs such as olanzapine. Moreover, although many animal models with metabolic side effects have been well defined, the interaction with other pathways has to be considered. The endocannabinoid system and the CB1 receptor (CB1R) are among the most promising central and peripheral targets involved in weight and energy balance. In this study we developed a rat model based 15-days treatment with olanzapine that shows weight gain and an alteration of the blood parameters involved in the regulation of energy balance and glucose metabolism...
April 1, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28368577/classics-in-chemical-neuroscience-aripiprazole
#19
Austen B Casey, Clinton E Canal
Aripiprazole was the first antipsychotic developed to possess agonist properties at dopamine D2 autoreceptors, a groundbreaking strategy that presented a new vista for schizophrenia drug discovery. The dopamine D2 receptor is the crucial target of all extant antipsychotics, and all developed prior to aripiprazole were D2 receptor antagonists. Extensive blockade of these receptors, however, typically produces extrapyramidal (movement) side effects, which plagued first-generation antipsychotics, such as haloperidol...
April 13, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28347393/brain-volume-changes-over-the-first-year-of-treatment-in-schizophrenia-relationships-to-antipsychotic-treatment
#20
R Emsley, L Asmal, S du Plessis, B Chiliza, L Phahladira, S Kilian
BACKGROUND: Progressive brain volume reductions have been described in schizophrenia, and an association with antipsychotic exposure has been reported. METHODS: We compared percentage changes in grey and white matter volume from baseline to month 12 in 23 previously antipsychotic-naïve patients with a first episode of schizophrenia or schizophreniform disorder who were treated with the lowest effective dose of flupenthixol decanoate depot formulation, with 53 matched healthy individuals...
March 28, 2017: Psychological Medicine
keyword
keyword
54097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"